448
Participants
Start Date
September 30, 2011
Primary Completion Date
September 30, 2013
Study Completion Date
January 31, 2014
Daclatasvir
Tablet, Oral, 60 mg, once daily, 24 weeks
Peg-Interferon Alfa-2a
Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
Ribavirin
Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
Montefiore Medical Center, The Bronx
Mercy Medical Center, Baltimore
Digestive Disease Associates, P.A., Baltimore
Metropolitan Research, Annandale
Mcguire D V A M C, Richmond
University Of North Carolina At Chapel Hill School Of Med, Chapel Hill
Carolinas Medical Center, Charlotte
Carolinas Center For Liver Disease, Statesville
Atlanta Medical Center, Atlanta
The Emory Clinic, Atlanta
Florida Hospital Transplant Center, Orlando
Miami V.A. Healthcare System, Maimi
University Of Miami, Miami
Triple O Research Institute, P.A., West Palm Beach
South Florida Center Of Gastroenterology, P.A., Wellington
Infectious Disease Research Institute, Inc, Tampa
Alabama Liver & Digestive Specialists (Alds), Montgomery
Digestive Health Center, Ocean Springs
Loyola University Medical Center, Maywood
Tulane University Health Sciences Center, New Orleans
Texas Clinical Research Institute, Arlington
Baylor College Of Medicine, Houston
Liver Associates Of Texas, Houston
Research Specialists Of Texas, Houston
Texas Liver Institute, San Antonio
Brooke Army Medical Center, San Antonio
Axis Clinical Trials, Los Angeles
Greater Los Angeles Healthcare System, Los Angeles
Va Long Beach Healthcare System - 11, Long Beach
Ucsd Antiviral Research Center (Avrc), San Diego
Precision Research Institute, Llc, San Diego
Medical Associates Research Group, Inc, San Diego
University Of California, Davis Medical Center, Sacramento
Oregon Health & Science University, Portland
The Research Institute, Springfield
Local Institution, San Juan
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY